August 20, 2025CancersOpen Access

A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Genomic alterations differ between NPM1-mutated and wild-type AML, indicating potential treatment targets.

NPM1 mutations are found in 15.1% of 4206 AML cases, predominantly in females, and are linked to several genomic alterations.
Key genomic alterations include FLT3, DNMT3A, and IDH1, which are more common in NPM1mut AML than NPM1wt AML.
Analysis utilized the FoundationOne Heme assay, comprising DNA and RNA sequencing for extensive genomic profiling.
Findings suggest that distinct mutation patterns in NPM1mut and NPM1wt AML could guide targeted therapy approaches.

Batayneh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

August 20, 2025CancersOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Genomic alterations differ between NPM1-mutated and wild-type AML, indicating potential treatment targets.

NPM1 mutations are found in 15.1% of 4206 AML cases, predominantly in females, and are linked to several genomic alterations.
Key genomic alterations include FLT3, DNMT3A, and IDH1, which are more common in NPM1mut AML than NPM1wt AML.
Analysis utilized the FoundationOne Heme assay, comprising DNA and RNA sequencing for extensive genomic profiling.
Findings suggest that distinct mutation patterns in NPM1mut and NPM1wt AML could guide targeted therapy approaches.

Batayneh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark